Zobrazeno 1 - 10
of 71
pro vyhledávání: '"E. Crucitta"'
Autor:
Francesco Di Costanzo, Salvatore Del Prete, Salvatore Siena, Paolo Pedrazzoli, Paola Pozzi, Antonio Farris, Alessandro Pappalardo, Roberto Labianca, Giuseppe Colucci, Giuseppe Fornarini, Clara Bianchessi, Alessandra Fabi, E. Crucitta, Federica Apolloni, Alberto Desogus, Antonio Santo, Simona Secondino, Daris Ferrari, Teresa Gamucci, Filomena Del Gaizo
Publikováno v:
Journal of Clinical Oncology. 26:1619-1625
Purpose Unresponsiveness to erythropoiesis-stimulating agents, occurring in 30% to 50% of patients, is a major limitation to the treatment of chemotherapy-related anemia. We have prospectively evaluated whether intravenous iron can increase the propo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ef54a9923dba6f95c4f63aa0ad3fdd8
https://doi.org/10.1200/jco.2007.12.2051
https://doi.org/10.1200/jco.2007.12.2051
Autor:
Silvia Novello, G.V. Scagliotti, Vittorio Franciosi, L. Crinò, Anna Ceribelli, L. Marini, Fausto Barbieri, Stefania Bartolini, Federico Cappuzzo, Vito Lorusso, F. De Marinis, E. Crucitta, Luciano Castaldini, M. Maur
Publikováno v:
British Journal of Cancer
This phase II study evaluated the response rate and tolerability of gemcitabine-oxaliplatin chemotherapy in non-small-cell lung cancer (NSCLC) patients. Chemonaive patients with stage IIIB or IV NSCLC received gemcitabine 1000 mg m(-2) on days 1 and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6da16c2df23eddcef2058a0b01fc3363
https://doi.org/10.1038/sj.bjc.6602667
https://doi.org/10.1038/sj.bjc.6602667
Autor:
C. D'Amico, Domenico Sambiasi, Michele Guida, A Latorre, A. Mazzei, Francesco Schittulli, E. Crucitta, L. Caporusso, Annamaria Catino, Pietro Calabrese, M. De Lena, N. Silvestris, Vito Lorusso
Publikováno v:
British Journal of Cancer
The purpose of this study was to determine the maximum-tolerated dose of gemcitabine plus mitoxantrone in women with metastatic breast cancer (MBC) and to evaluate activity and toxicity of this combination in a phase II trial. Sixty-three patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9aaed329eb447cc50b44454775bde810
http://europepmc.org/articles/PMC2377160
http://europepmc.org/articles/PMC2377160
Autor:
S. Mancarella, F. Carpagnano, N. Panza, Domenico Sambiasi, Michele Guida, Nicola Silvestris, M. De Lena, E. Crucitta, Vito Lorusso
Publikováno v:
Annals of Oncology. 13:1862-1867
Background The aim of our study was to determine the maximum tolerated dose of paclitaxel combined with a fixed dose of gemcitabine and vinorelbine in the treatment of non-small-cell lung cancer (NSCLC) and to evaluate in a phase II trial the efficac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::046b983cd6e567ce0adb9d9c66c00417
https://doi.org/10.1093/annonc/mdf308
https://doi.org/10.1093/annonc/mdf308
Autor:
Michael Alschibaja, F. Pinto, Wen-Chi Chen, Ömür Ataoğlu, Ayhan Verit, Jörg Massmann, Angelo Porreca, Ali Unsal, Giampaolo Delicato, Ming-Tsung Lai, Giulio Nicita, Destito A, Tahsin Turunc, Pierre Mongiat-Artus, John P. Gearhart, Muzaffer Eroğlu, Maria Cristina Paoletti, Aylin Kanli, Alessandro D'Addessi, N.S. Johal, Pranjal R Modi, Michele Marzocco, S.N. Jayasena, Francois Desgrandchamps, E. Crucitta, L. Apthorp, Fuu-Jen Tsai, Mete Kilciler, I.M. Tavolini, R.O. Plail, Chung-Hsiung Huang, S. Corvin, Hale Maral Kir, Mustafa Cengiz, Chih-Ming Lu, Eugenio Di Grazia, Rajiv Yadav, Anis Aribogan, Chao-I Wu, Marco Racioppi, Stéphane Milcent, Wolfgang Sturm, Meng-Chu Chung, Fikret Erdemir, Surendra B. Kolla, Dominic Frimberger, Yasar Ozgok, M. Zucchetti, C. Kouriefs, L. Managadze, Zaza Mezvrishvili, Roger Paul, Maria Teresa Filocamo, Oguz Acar, Gagan Gautam, Meltem Ozlen Dillioglugil, Rajiv Goel, D.M.R. Gunawardena, Markus A. Kuczyk, Ersin Çimentepe, V. De Marco, Koray Erten, Armin Funk, M. Derya Balbay, Sharad Dodia, Monish Aron, Jean Marc Duclos, Ercan Yeni, Ashok K. Hemal, Hasan Bakırtaş, Lei Wan, M. V. C. De Silva, Ying-Chin Ko, Donata Villari, Selahattin Bedir, Dario Nicolosi, Aristotelis G. Anastasiadis, Dogan Unal, Rudolf Hartung, F. Longo, Atilla Aridogan, J.T.N. Ariyasinghe, Pierre Teillac, Nazario Foschi, Mathias Wegner, Hsi-Chin Wu, Paul Meria, L. Marini, Hacı Kahya Ozdogan, P. Bassi, S.A.S. Gunawardena, Sule Akin, F. Dal Moro, E. Dattolo, Arnulf Stenzl, Narmada P. Gupta, Vincenzo Li Marzi, Onder Ors, Huey-Yi Chen, Ozdal Dillioglugil, Mehmet Doğan Gülkaç, Hidayet Coban
Publikováno v:
Urologia Internationalis. 75:381-383
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::075b81ab9cce9f562612189ec31ebd46
https://doi.org/10.1159/000090127
https://doi.org/10.1159/000090127
Autor:
Francesco Pinto, Fabrizio Longo, Massimo Zucchetti, F. Dal Moro, P.F. Bassi, V. De Marco, E Crucitta, L Marini, I.M. Tavolini
Introduction: Gemcitabine, a chemotherapeutic agent, has been shown to be active against transitional cell cancer of the bladder. The aim of the study was to determine the pharmacokinetic profile of gemcitabine, administered intravesically in patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efb44e53cf017aa0f8810c780a273800
http://hdl.handle.net/11577/2529003
http://hdl.handle.net/11577/2529003
Autor:
L. Marini, N. Locopo, Vito Lorusso, M. De Lena, E. Crucitta, G. Andreola, N. Silvestris, M. D'Aprile
Publikováno v:
International journal of oncology. 24(2)
Many active cytotoxic drugs and several regimens exist for breast cancer therapy. However, these conventional treatments have not changed the outcome of patients with locally advanced and metastatic disease. As a consequence, the dynamic balance betw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c38d8827e4c1dd99f71b427f25f1ccf2
https://pubmed.ncbi.nlm.nih.gov/14719116
https://pubmed.ncbi.nlm.nih.gov/14719116
Autor:
M. De Lena, E. Crucitta, Nicola Silvestris, Vito Lorusso, Maria Grazia Fiore, Domenico Piscitelli
Publikováno v:
Journal of chemotherapy (Florence, Italy). 15(5)
Primary leiomyosarcomas (LMSs) of the lung are extremely rare malignancies that have been the subject of single or small series of case reports. Today, the gold standard of treatment in patients with locally advanced and metastatic disease includes o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0e540efdc5bb8bf61126257902ed259
https://pubmed.ncbi.nlm.nih.gov/14603882
https://pubmed.ncbi.nlm.nih.gov/14603882
Autor:
E. Crucitta, M. De Fazio, Antonia Gentile, M. De Lena, D. Sanbiasi, S. Benvestito, Mic Guida, Antonio Cramarossa
Publikováno v:
Melanoma research. 12(6)
Both primary and metastatic melanoma of the gallbladder are rare. Involvement of the gallbladder occurs in about 15% of all gastrointestinal metastatic localizations in post-mortem case records. It is often difficult to differentiate primary from met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0e071d563cf8d28c6c8c1cc9e125867
https://pubmed.ncbi.nlm.nih.gov/12459652
https://pubmed.ncbi.nlm.nih.gov/12459652
Autor:
F. Del Gaizo, S. Mancarella, Antonio Farris, S. Palmeri, Annunziato Iannelli, G. De Cataldis, Salvatore Tafuto, Pasquale Comella, L. De Lucia, E. Crucitta, F. De Vita, F. Buzzi, Luigi Maiorino
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 13(6)
Purpose: The purpose of this study was to compare the activity and toxicity of the combination of irinotecan (IRI) plus folinic acid (FA)-modulated 5-fluorouracil (5-FU) i.v. bolus with a regimen of double modulation of 5-FU with methotrexate (MTX) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5608e20dd001076c228fd9fc8350eb4d
https://pubmed.ncbi.nlm.nih.gov/12123331
https://pubmed.ncbi.nlm.nih.gov/12123331